N-Acetyl Semax Amidate: what the studies show, status and safety
Summary
N-Acetyl Semax Amidate is a sales name for a modified form of Semax, a peptide sold as a prescription medicine in Russia. Both ends of the chain are chemically capped. The earliest trace found is an online shop page from 2015 announcing that change. The only peer-reviewed paper found on the exact molecule describes a laboratory test method and contains no biological data. No approval was found in any market checked, and Semax doses must not be carried over to it. In sport it is banned at all times.
Key findings at a glance
- The earliest trace leads to a shop, not a laboratory. On 6 February 2015 an online seller wrote of its new product: "Not only did we acetylate the N-terminus …, but we also amidated the C-terminus" [1].
- Only one peer-reviewed paper found on the exact molecule, and it is analytical. A Belgian drug-control laboratory used it in 2020 as a reference material for a test method. The paper contains no data on effects or safety [2].
- No biological study found. Searches of PubMed, Europe PMC and ClinicalTrials.gov on 23 September 2026 returned no cell, animal or human study. The control search for Semax returns 232 PubMed records [3], [4], [5], [6].
- A seller admits the gap. A Russian shop that sells the substance writes that it is on the market "despite the absence of scientific data" on its effects in the body [7].
- The database entry comes from sales catalogues. The PubChem record was created on 31 December 2024. All of its deposits come from chemical sellers, and it links to no literature, patent or bioassay [8].
- The closest related research found points the other way. In a 2016 cell study, adding the acetyl cap to Semax removed a protective effect that plain Semax showed. That study did not test the amidated form [9].
- Banned in sport at all times. No approval was found in any market checked, so category S0 of the 2026 Prohibited List applies. Its parent substance Semax is a prescription medicine in Russia, but that registration names only the unmodified chain [10], [11].
What it is
The substance is Semax with two small chemical changes. Semax is a chain of seven amino acids, the building blocks of proteins. It is licensed as a prescription medicine in Russia [11]. Here an acetyl group caps the front end of the chain (acetylation) and an amide group caps the back end (amidation) [8].
No university, institute or company was found to have claimed the molecule, and no paper introducing it was found. The earliest trace found is a product page of an online research-chemical shop, archived on 6 February 2015 [1]. The same shop had offered the acetylated-only form since at least 20 November 2014 [12].
The name is a trade name coined by sellers, not an official drug name. No substance code (UNII) with the American regulator could be found [13], [1]. Chemically it is a very close relative of a prescription medicine, but it is not that medicine. Semax itself is covered on the Semax page.
Quick facts
| Field | Value | Ref |
|---|---|---|
| Sales names | N-Acetyl Semax Amidate, NA-Semax-Amidate, Ac-Semax-NH2 | [8], [7] |
| Sequence | Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2, seven amino acids | [2], [8] |
| Parent substance | Semax, Met-Glu-His-Phe-Pro-Gly-Pro | [14] |
| Formula and mass | C39H54N10O10S, 855.0 g/mol; exact mass 854.3745 Da | [2], [8] |
| PubChem CID | 172638603, created 31 December 2024 from seller deposits | [8] |
| InChIKey | QQOAKFVAEDCKGY-HPMAGDRPSA-N | [8] |
| CAS registry number | 2920938-90-3, supplied by sellers and not checked against the CAS register | [8] |
| UNII | None found | [13] |
| How long it lasts in the body | No published value found | [3] |
| Registered studies in people | None found | [5] |
| Approval status | No approval found in any market checked | [15], [16], [11] |
| Earliest trace | A US shop page, 6 February 2015 | [1] |
A word of caution on identifiers. Some directories attach PubChem CID 9811102 to this name. That record is Semax itself, with the formula C37H51N9O10S and 813.9 g/mol [14]. The acetylated-only form has yet another record, CID 172107353 [17].
How it works
This is unknown. No study found has tested this molecule on a receptor, a cell, an animal or a person [3], [4]. What circulates instead are claims made by sellers, and each can be checked against what research actually exists.
- "Acetylation carries it into the brain." The 2015 shop page gives this as the reason for the acetyl cap [1]. No study found has measured brain uptake for this molecule, or for any capped form of Semax [3], [4].
- "Both caps protect it from breakdown." A 2013 laboratory paper examined how quickly acetylated Semax breaks down [18]. Its title names only the acetylated form, and its figures could not be checked against the original text.
- "It is stronger than Semax." No study found compares the two. The only cell study found on acetylated Semax showed that the change removed a protective effect [9].
- "It raises BDNF, a growth factor in the brain, and improves memory." These are findings from Semax research. No report of them for this molecule was found [3].
The common thread is borrowing. Every mechanism claim found for the substance was taken from Semax, or from a related but different molecule. Small changes at the ends of a peptide can change how it binds, how fast it breaks down and where it goes in the body. That is why findings cannot simply be carried over.
What the trials found
No trials were found. The searches found no registered study in people, no published animal experiment and no cell study of this molecule [3], [4], [5]. One paper describes the molecule chemically, and two papers describe a related but different one.
The one paper on the exact molecule
Analytical study In 2020 Sciensano, the Belgian public-health laboratory that tests seized medicines, published a method for detecting ten peptides sold online as brain boosters [2]. It had the amidated molecule made to order at more than 95 per cent purity as a reference material.
In the test it came out of the separation column at 10.26 minutes. Semax came out at 8.70 minutes and acetylated-only Semax at 10.89 minutes, so the method tells all three apart [2]. Tested on 30 samples, the method picked up each of the ten peptides at its screening limit of 10 µg/ml, with no false positive or false negative results.
The paper proves only that the molecule can be made and detected. It contains no data on effects, safety or how the body handles it. Sciensano included it because an online search showed it on sale. The two seized samples described in the paper contained Selank and Semax, not this variant [2].
How the searches were run
Each search was paired with a control that should find something, so an empty result means nothing was found rather than a broken search.
- PubMed. "N-acetyl semax" and "Ac-MEHFPGP" returned no records. "Ac-Semax" returned one, the 2016 cell study of the acetylated-only form. The control search "semax" returned 232 records on 24 September 2026 [3], [6].
- Europe PMC, including full texts. "N-acetyl semax amidate", "Ac-Semax-NH2", "Semax-NH2" and "semax amidate" returned no records. The control paper was found through the same interface [4].
- ClinicalTrials.gov. No registered study was found under any spelling. The search for Semax itself also returned none [5].
- Substance databases. The American substance register holds a record for Semax but none for this variant. The ChEMBL database returned no entry for its structure key, but it holds no Semax entry either, so that result carries little weight [13], [19].
- Patents. No patent found reports experimental data on this molecule. One application names acetylated Semax only in the free-acid form, without data [20].
Evidence about acetylated Semax, a different molecule
Two published papers are often cited as if they applied here. Both concern Semax with only the acetyl cap, and neither reports on the amidated form. They are analogies, not evidence about this substance.
Cell study, different molecule A 2016 study compared how Semax and acetylated Semax bind copper and zinc [9]. The acetyl cap changed how copper was held. In a human nerve cell line grown in a dish, acetylated Semax no longer protected against copper damage. The authors put this down to the free front end of plain Semax.
Laboratory study, different molecule A 2013 paper examined how well acetylated Semax resists breakdown by enzymes and in rat tissue [18]. Sellers summarise it as more stable than Semax. PubMed holds no abstract, and the original text could not be checked, so the figures quoted online are not repeated here.
A 2025 study in a mouse model of Alzheimer's disease is also cited as a "Semax derivative" result. It tested a different peptide with two amino acids swapped, not this variant [21].
What is still unknown
- Whether it does anything. No measured effect in cells, animals or people was found [3], [4].
- What the body does with it. No data on uptake, breakdown, half-life or brain entry were found [3].
- Whether it is safe. No toxicology study of any kind was found [3], [4].
- Whether the caps keep Semax's actions. No study found has checked, and the one related cell study found a loss [9].
Side effects and safety
No side-effect profile could be found, and that is not the same as being safe. No published study was found in which people or animals received the molecule, so no recorded side effects were found either [3], [5].
What can be said comes from regulators' work on Semax itself, which covers the variant only indirectly.
- Mix-ups under one name. The FDA wrote in 2026 that it "has encountered multiple salts, and derivatives, including different active moieties, sold commercially under the same common name" [22]. It called this a safety risk, because patients may receive a different substance from the one ordered.
- Blurred records. PubChem removed a synonym from this variant's record that actually names Semax. Seller catalogues appear to mix the two up [8].
- Immune reactions. For Semax the FDA could not rule out immune reactions caused by impurities and clumped peptide. No such assessment of the variant was found [22].
- One report for the whole family. The FDA found a single report in its side-effect database for all Semax-related substances up to 3 December 2025 [22].
- No quality standard. No pharmacopoeia monograph or approved specification was found. Purity figures on shop pages are the sellers' own statements [22], [23].
What was not found
None of the following turned up in the searches described on this page:
- Toxicology: single-dose or repeat-dose studies, or tests for damage to genes, fertility or unborn young.
- Data on uptake, breakdown or brain entry, or a half-life.
- Testing for immune reactions, or interaction data.
- Data of any kind from people.
- Published evidence that the two caps preserve any effect of Semax.
Why this page lists no doses
Every dose in this register comes from a published study, with its population, duration and source. No study of this molecule was found, so there is no study dose to report [3], [5].
Doses of Semax must not be carried over either. Semax is a different substance and a prescription medicine in Russia, so the Semax page lists no doses of its own [11]. Small changes at the ends of a peptide can alter how it acts, so an amount that belongs to one molecule says nothing about the other. Amounts on sales pages come from sales copy rather than measurement, so they are not repeated here.
Development and approval status
From a Russian medicine to a shop variant
- 1994Semax registered in RussiaThe parent substance; every current Russian entry is prescription only, ref [11]
- November 2014Acetylated Semax on saleAn online research-chemical shop offers the acetylated-only form, ref [12]
- February 2015The amidated version appearsThe same shop writes that it also amidated the chain end, ref [1]
- 2016Cell study of acetylated SemaxThe acetyl cap removes a protective effect; amidated form not tested, ref [9]
- 2020Belgian test methodThe molecule is used as a reference material, with no biological data, ref [2]
- December 2024PubChem record createdFilled entirely from seller catalogues, ref [8]
- May 2026FDA review of SemaxWarns of derivatives sold under the same name; the variant itself is not assessed, ref [22]
No development of the substance was found. No sponsor, programme or study plan came to light, and none of the searches described above found an experiment on it. Everything found points to a trade article.
The naming pattern supports this. The same shop listed "N-acetyl epitalon amidate" from September 2015 and "N-acetyl selank amidate" from October 2015. A GHK version followed in 2019. The same two caps were applied to one peptide after another, and the archive records only the product pages, not any research behind them [24].
| Market | Status | Note | Ref |
|---|---|---|---|
| United States | No approval found | No drug, label or product listing found; not on the FDA compounding lists | [25], [15] |
| European Union | No approval found | No entry in the European medicines dataset | [16] |
| Germany | No approval found | No EU approval; national database not queried | [16] |
| United Kingdom | No approval found | Database not machine-readable; no approval found elsewhere | [16] |
| Australia | No approval found | Not named in the Poisons Standard | [26] |
| Canada | No approval found | Ingredient database returns nothing | [27] |
| Switzerland | No approval found | Not in the list of authorised medicines | [28] |
| Russia | No registration found | Semax is registered, prescription only; no entry for the variant | [11] |
The Russian row needs care. Russia's state drug register holds 31 Semax entries, all for the unmodified seven-amino-acid chain. None contains an acetyl or amide group, and a search for "acetyl semax" returned nothing [11].
Each registration names that exact sequence as its active substance. The variant differs from it only by the two caps, which makes it a very close relative of a prescription medicine. Even so, it has a different formula and mass, so the Semax registration does not cover it. It does not follow that the variant may be sold freely either. No registration was found for it at all, while its parent substance is prescription only [11].
Two further entries need a note. On 6 September 2026, when the Semax page was researched, the American product database still held a bulk listing for "N-acetyl Semax"; by 23 September it could no longer be retrieved [15]. Which form that listing meant is unclear.
Not being named in the Australian Poisons Standard is not permission, because unapproved medicines need approval regardless [26]. All searches for this table were run on 23 September 2026.
Anti-doping
The substance is banned at all times, in and out of competition. Category S0 of the 2026 Prohibited List covers "any pharmacological substance … with no current approval by any governmental regulatory health authority for human therapeutic use" [10].
This is where the variant differs from Semax. Semax holds a current Russian approval, so on its wording S0 does not clearly reach it, and its position is disputed [29], [10]. No approval for the variant was found in any market checked, so S0 applies without that doubt.
The list also bans corticotrophins, the hormones that drive the adrenal glands, under S2.2.2. No measurement of any hormone action of the variant was found, so this cannot be settled. Either way the result is the same: banned at all times [10].
The annex to German anti-doping law lists corticotrophins, and a closing clause extends every entry to "derivatives". Whether a capped seven-amino-acid analogue of a hormone fragment counts as such a derivative is unclear, and no court or authority decision on it was found. The question is legally open [30].
The Belgian method can detect the molecule in seized products. It is not a urine or blood test for athletes [2]. More detail is in the overview of peptides banned in sport.
Compared with related peptides
PubMed searches repeated on 24 September 2026. The single Ac-Semax record is the 2016 cell study of the acetylated-only form. The one paper found on the amidated molecule names it only in a table of its full text, which a PubMed search does not reach. Sources [3], [6].
| Substance | Structure | Status | Peer-reviewed work found on the exact molecule | PubChem |
|---|---|---|---|---|
| Semax | Met-Glu-His-Phe-Pro-Gly-Pro | Prescription medicine in Russia [11] | 232 PubMed records [6] | CID 9811102 [14] |
| Acetylated Semax | Ac-Met-Glu-His-Phe-Pro-Gly-Pro | No approval found | Two laboratory papers [9], [18] | CID 172107353 [17] |
| N-Acetyl Semax Amidate | Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2 | No approval found | One analytical paper [2] | CID 172638603 [8] |
| Adamax | Disputed; described as Semax with an adamantane group | No approval found | None found | None found |
The comparison is not about strength. It shows how quickly the evidence thins out as each chemical change is added. Semax has a Russian approval and 232 PubMed records. For the acetylated form, two laboratory papers were found. For the amidated form, one analytical paper and a catalogue entry were found.
The names add to the confusion. "N-Acetyl Semax" is commonly used for the acetylated-only form, yet PubChem lists it as a synonym of the amidated record too [8], [17]. Adamax is a separate seller product and not a synonym for this variant; its own page explains why.
Common misconceptions
- "It is an improved Semax that shares its research." The Russian approval, the clinical reports and the animal studies all concern Semax. The variant is a different substance with its own formula and database record [8], [14], [11].
- "N-acetyl Semax and N-Acetyl Semax Amidate are the same." They are not. The first carries only the acetyl cap and has its own record. The Belgian laboratory separates the two by retention time [2], [17].
- "A PubChem entry and a CAS number show it has been researched." The record was built from seller catalogues in December 2024 and links to no literature. A registry number shows only that someone offers the substance [8].
- "The caps make it stronger." No comparison was found. In the only cell study found on acetylated Semax, the cap removed a protective effect [9].
- "It was studied in animals for stroke and memory." Those studies were done with Semax. None was found for this variant [3], [4].
- "Semax is not clearly banned in sport, so neither is this." The opposite holds. No approval for the variant was found in any market checked, so S0 applies directly [10].
Frequently asked questions
Are there any studies on N-Acetyl Semax Amidate?
Only one was found, and it measures no effects. A Belgian drug-control laboratory used the molecule in 2020 as a reference material for a detection method. Searches on 23 September 2026 found no cell, animal or human study, while the same PubMed search found 232 records on Semax.
Who invented N-Acetyl Semax Amidate?
No research group was found to have claimed it. The earliest trace found is the page of an online research-chemical shop from 6 February 2015. The shop wrote that it had acetylated one end of Semax and also amidated the other.
Is N-Acetyl Semax Amidate the same as Semax?
No. It is Semax with two chemical caps added, which gives it a different formula, mass and database record. Findings about Semax, including its Russian approval, do not transfer to it.
Is N-Acetyl Semax Amidate approved as a medicine anywhere?
No approval was found in any of the eight markets checked on 23 September 2026. Russia's register lists Semax on prescription only, and a search of it found no entry for the capped variant.
Is N-Acetyl Semax Amidate stronger than Semax?
No evidence for that claim was found, and no study comparing the two was found. The only cell study found on acetylated Semax showed that the acetyl cap removed a protective effect, and it did not test the amidated form.
Is N-Acetyl Semax Amidate banned in sport?
Yes, at all times. Category S0 of the 2026 Prohibited List covers substances that no health authority has approved for use in people. Unlike Semax, no approval for the variant was found in any market checked, so the doubt that surrounds Semax does not arise.
Is N-Acetyl Semax Amidate safe?
That cannot be answered, because no safety test of it was found. No toxicology, no study of how the body handles it and no data from people were found. The FDA also warns that different Semax derivatives are sold under the same name.
Why does this page list no doses for N-Acetyl Semax Amidate?
No study of the molecule was found, so there is no study dose to report. Semax doses must not be carried over either, because Semax is a different substance and a prescription medicine in Russia. Amounts on sales pages are sales copy, not measurements.
Sources
- Online research-chemical shop. Product page "N-Acetyl Semax Amidate Solution", Internet Archive capture 20150206051604 of 6 February 2015. Seller source, cited as evidence of what was claimed. Not linked.
- Vanhee C, Francotte A, Janvier S, Deconinck E (2020). The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: an incentive for controlling agencies to prepare for future encounters of the kind. Drug Testing and Analysis 12(3):371-381. PMID 31667971. DOI 10.1002/dta.2717. Table 1 lists N-acetyl semax amidate, Ac-MEHFPGP-NH2, exact mass 854.3745, retention time 10.26 minutes. https://sciensano.be/sites/default/files/dta_nootropic_peptides.pdf
- PubMed, NCBI E-utilities. Searches for "N-acetyl semax" (0 records), "Ac-MEHFPGP" (0), "Ac-Semax" (1, PMID 27586814), "semax amidate" (6, all unrelated) and "acetyl* AND semax" (7, two concerning acetylated Semax). Retrieved 23 September 2026. https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22N-acetyl+semax%22
- Europe PMC, REST search including full texts. Queries "N-acetyl semax amidate", "N-acetyl semax", "Ac-Semax-NH2", "Semax-NH2", "NA-Semax" and "semax amidate" (0 records each); control query "Ac-Semax" (1 record). Retrieved 23 September 2026. https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%22N-acetyl%20semax%20amidate%22
- ClinicalTrials.gov, API v2. Queries "N-acetyl semax", "NA-Semax", "semax amidate" and "semax"; each returned a total count of zero. Retrieved 23 September 2026. https://clinicaltrials.gov/api/v2/studies?query.term=N-acetyl%20semax&countTotal=true
- PubMed, NCBI E-utilities, repeat searches of 24 September 2026: "semax" 232 records; "N-acetyl semax" 0; "Ac-MEHFPGP" 0; "Ac-Semax" 1. ClinicalTrials.gov query "semax" on the same day: total count zero. https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=semax
- Russian seller article "Semax и его аналоги. N-Acetyl-Semax и Semax-Amide", retrieved 23 September 2026. States that the substance is on sale "несмотря на отсутствие научных данных о воздействии на организм" (despite the absence of scientific data on its effects in the body). Seller source. Not linked.
- PubChem. Compound CID 172638603, N-acetyl semax amidate, C39H54N10O10S, 855.0 g/mol. Created 31 December 2024; all deposits from chemical sellers; no literature, patent or bioassay sections. Retrieved 23 September 2026. https://pubchem.ncbi.nlm.nih.gov/compound/172638603
- Magrì A, Tabbì G, Giuffrida A, Pappalardo G, Satriano C, Naletova I, Nicoletti VG, Attanasio F (2016). Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. Journal of Inorganic Biochemistry 164:59-69. PMID 27586814. DOI 10.1016/j.jinorgbio.2016.08.013. Abstract read; full text not accessible.
- World Anti-Doping Agency. The 2026 Prohibited List, in force from 1 January 2026, sections S0 and S2.2.2. Full-text search for "semax", "selank" and "acetyl" returned no match. https://www.wada-ama.org/en/prohibited-list
- State Register of Medicines of the Russian Federation (GRLS), via the mirror pharmcontrol.ru. Query "семакс": 31 entries, all for Met-Glu-His-Phe-Pro-Gly-Pro, current entries prescription only; the original 1994 entry was deleted on 30 December 2003. Query "ацетил семакс": 0 entries. Retrieved 23 September 2026. https://www.pharmcontrol.ru/registry/drugs/?q=семакс
- Online research-chemical shop. Product page "N-Acetyl Semax Solution", Internet Archive capture 20141120215411 of 20 November 2014. Seller source, cited as evidence of what was claimed. Not linked.
- Global Substance Registration System (GSRS), FDA and NCATS. Search for "N-acetyl semax" returned 0 records; control search "semax" returned 1 record, UNII I5FAL2585H. Retrieved 23 September 2026. https://gsrs.ncats.nih.gov/api/v1/substances/search?q=%22N-acetyl%20semax%22
- PubChem. Compound CID 9811102, ACTH (4-7), Pro-Gly-Pro-, the record for Semax, C37H51N9O10S, 813.9 g/mol. Retrieved 23 September 2026. https://pubchem.ncbi.nlm.nih.gov/compound/9811102
- openFDA. Queries of drug/ndc.json, drug/drugsfda.json and drug/label.json for "acetyl semax", "n-acetyl semax" and "semax amidate" returned not found; the control query "semax" in drug/ndc.json returned 9 bulk listings, none for the variant. Retrieved 23 September 2026. https://api.fda.gov/drug/ndc.json?search=semax&limit=50
- European Medicines Agency. Medicines output, medicines JSON report, 2,746 records, timestamp 23 September 2026; "semax" not found, control term "semaglutide" present. https://www.ema.europa.eu/en/documents/report/medicines-output-medicines_json-report_en.json
- PubChem. Compound CID 172107353, Ac-Met-Glu-His-Phe-Pro-Gly-Pro-OH, the acetylated-only form, C39H53N9O11S. Retrieved 23 September 2026. https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/fastformula/C39H53N9O11S/cids/JSON
- Shevchenko KV, Nagaev IY, Andreeva LA, Shevchenko VP, Myasoedov NF (2013). Stability of Semax acetyl to proteolysis in various biological media. Doklady Biological Sciences 449:110-112. PMID 23652441. DOI 10.1134/S0012496613020166. No abstract in PubMed; original text not accessible.
- ChEMBL. Query by InChIKey QQOAKFVAEDCKGY-HPMAGDRPSA-N returned 0 molecules. Retrieved 23 September 2026. https://www.ebi.ac.uk/chembl/api/data/molecule.json?molecule_structures__standard_inchi_key=QQOAKFVAEDCKGY-HPMAGDRPSA-N
- Huici BT, Hallstat Capital LLC (2024). Combination therapy with semax and cannabidiol. US20240269226A1, priority 7 February 2023. Names N-acetyl-Semax only in the free-acid form, without experimental data. https://patents.google.com/patent/US20240269226A1/en
- Radchenko AI, Kuzubova EV, Apostol AA et al. (2025). The potential of the peptide drug Semax and its derivative for correcting pathological impairments in the animal model of Alzheimer's disease. Acta Naturae 17(4):110-120. PMID 41479572. DOI 10.32607/actanaturae.27808. The derivative studied is Met-Glu-Asp-Arg-Pro-Gly-Pro.
- FDA (2026). Briefing document: evaluation of semax-related bulk drug substances. Pharmacy Compounding Advisory Committee, document dated 11 May 2026, section II.A on salts and derivatives sold under the same name. Retrieved 23 September 2026. https://www.fda.gov/media/193348/download
- Russian seller product page for Ac-Semax-NH2, archived since 4 December 2020. States "CAS No.: N/A", purity above 97 per cent and the formula C39H54N10O10S. Seller source, cited as evidence of what is claimed. Not linked.
- Internet Archive, capture index for the shop domain, showing product pages for amidated Semax (2015), N-acetyl epitalon amidate (11 September 2015), N-acetyl selank amidate (8 October 2015) and N-acetyl GHK amidate (2019). Seller source, cited as evidence of what was offered. Not linked.
- FDA (2026). Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026; lists Semax, not the variant. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- Therapeutic Goods Administration. Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. Full-text search for "semax" returned no match; controls BPC-157, Melanotan II and corticotrophin found. Retrieved 23 September 2026. https://www.legislation.gov.au/
- Health Canada. Drug Product Database API, active-ingredient query "semax" returned an empty list; control query "acetyl" returned 378 records. Retrieved 23 September 2026. https://health-products.canada.ca/api/drug/activeingredient/?lang=en&type=json&ingredientname=semax
- Swissmedic. List of authorised human medicines, status 31 August 2026; "semax" not found, control names present. https://www.swissmedic.ch/swissmedic/de/home/services/listen_neu.html
- Pokrywka A, Surala O, Grabowska K et al. (2025). "Brain doping" substances: prohibited or not in sports? Biology of Sport 42(4):189-201. PMID 41048238. DOI 10.5114/biolsport.2025.150047. Places Semax in the category of unclear status; the variant is not mentioned.
- Germany. Annex to section 2(3) of the Anti-Doping Act (Anti-Doping-Gesetz), Federal Law Gazette 2023 I No. 67, section II.2.2 on corticotrophins and the closing clause on derivatives. https://www.gesetze-im-internet.de/antidopg/anlage.html
Cite this page
The searches behind this page were run on 23 September 2026 and partly repeated on 24 September 2026. For a substance known almost only from negative search results, the date is part of the finding.
myPeptides Research & Editing. (2026). N-Acetyl Semax Amidate: what the studies show, status and safety. Version 1.0, 24 September 2026. myPeptides Peptide Register. Retrieved from https://mypep.app/peptides/n-acetyl-semax
How pages in this register are compiled and graded is described under methodology; the full register is at peptides.
| Version | Date | Change |
|---|---|---|
| 1.0 | 2026-09-24 | Initial publication |
Last verified: 24 September 2026. Next review: on any peer-reviewed publication about this molecule, a change to the Russian Semax registrations, or a change in the anti-doping classification.